Waters (NYSE:WAT – Get Free Report) had its target price boosted by analysts at UBS Group from $405.00 to $410.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage currently has a “neutral” rating on the medical instruments supplier’s stock. UBS Group’s price target points to a potential upside of 7.81% from the company’s current price.
A number of other equities research analysts also recently weighed in on WAT. Cfra set a $389.00 target price on shares of Waters in a research note on Thursday, October 17th. Stifel Nicolaus lifted their price target on shares of Waters from $332.00 to $360.00 and gave the stock a “hold” rating in a research note on Monday, November 4th. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Waters from $310.00 to $325.00 and gave the stock a “hold” rating in a research note on Monday, November 4th. TD Cowen lifted their price target on shares of Waters from $363.00 to $410.00 and gave the stock a “hold” rating in a research note on Monday, November 4th. Finally, Sanford C. Bernstein raised shares of Waters from a “market perform” rating to an “outperform” rating and set a $430.00 price target on the stock in a research note on Friday, January 10th. Ten equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Waters presently has a consensus rating of “Hold” and an average target price of $390.07.
Read Our Latest Analysis on Waters
Waters Price Performance
Waters (NYSE:WAT – Get Free Report) last announced its earnings results on Wednesday, February 12th. The medical instruments supplier reported $4.10 earnings per share for the quarter, beating analysts’ consensus estimates of $4.02 by $0.08. Waters had a net margin of 21.43% and a return on equity of 49.93%. As a group, sell-side analysts anticipate that Waters will post 11.79 EPS for the current year.
Institutional Trading of Waters
Several large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in Waters by 0.3% in the fourth quarter. Vanguard Group Inc. now owns 7,098,668 shares of the medical instruments supplier’s stock valued at $2,633,464,000 after acquiring an additional 19,456 shares in the last quarter. Wealthfront Advisers LLC boosted its holdings in Waters by 106,144.4% in the fourth quarter. Wealthfront Advisers LLC now owns 3,087,461 shares of the medical instruments supplier’s stock valued at $1,145,386,000 after acquiring an additional 3,084,555 shares in the last quarter. Alliancebernstein L.P. boosted its holdings in Waters by 8.7% in the fourth quarter. Alliancebernstein L.P. now owns 2,654,002 shares of the medical instruments supplier’s stock valued at $984,582,000 after acquiring an additional 212,364 shares in the last quarter. State Street Corp boosted its holdings in Waters by 1.9% in the third quarter. State Street Corp now owns 2,577,733 shares of the medical instruments supplier’s stock valued at $927,700,000 after acquiring an additional 49,194 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Waters by 2.5% in the fourth quarter. Geode Capital Management LLC now owns 1,451,445 shares of the medical instruments supplier’s stock valued at $537,053,000 after acquiring an additional 34,762 shares in the last quarter. Institutional investors own 94.01% of the company’s stock.
Waters Company Profile
Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.
Recommended Stories
- Five stocks we like better than Waters
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Buffett Buys More Occidental Petroleum—Sticking to His Playbook
- What is the Shanghai Stock Exchange Composite Index?
- CVS Health: Earnings Beat Ignites Stock Rally
- Pros And Cons Of Monthly Dividend Stocks
- Honeywell’s Breakup: Is HON Stock a Sweet Deal for Investors?
Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.